What Happened?
San Ramon, CA-based BioClin Therapeutics Inc Appointed Stephen Lau as Chief Executive Officer
About the Company
BioClin Therapeutics, Inc. is a privately-held biotechnology developing biologics to address medical conditions where there is significant unmet need. Our lead program is a human monoclonal antibody, B-701, that targets and blocks the activity of FGFR3 (fibroblast growth factor receptor 3) and is the most advanced FGFR3-specific antagonist in development. B-701 has been tested in two Phase 1 clinical trials involving 40 patients and demonstrated potential efficacy in patients with metastatic bladder cancer who were receiving it as 2nd line therapy.
About the Person
Stephen Lau is Chief Executive Officer at BioClin Therapeutics Inc. Previously, Stephen held various senior HR leadership roles in the industry.
Info Source
News
Short Profile